By paying $35 million, Walgreens settled allegations by pharmacist-whistleblower Bernard Lisitza that it unlawfully defrauded Medicaid by switching prescriptions for ranitidine, the generic form of the brand-name drug Zantac®, and fluoxetine, the generic form of Prozac®. The United States, Puerto Rico, 42 states, and the qui tam relator claimed that Walgreens improperly caused its pharmacies to switch Medicaid patients’ prescriptions from ranitidine tablets to ranitidine capsules, and from fluoxetine capsules to fluoxetine tablets. The alleged Medicaid fraud covered by the settlement lasted for more than four years, from July 16, 2001 through at least December 31, 2005. The complaint was brought in 2003 under the qui tam provisions of federal and state False Claims Acts, after whistleblower relator Bernard Lisitza uncovered the conduct and reported the problem to the government. The investigation and prosecution was led by the Attorneys General Offices in Florida, Illinois, Ohio, Texas and several other states, and by the United States Attorney’s Office in Chicago. Qui tam Relator Lisitza pursued the case with the assistance of his attorneys, Michael I. Behn and Linda Wyetzner, of Behn & Wyetzner, Chartered, in Chicago.